Cargando…
Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
Non-small-cell lung cancer (NSCLC) is a major health burden, and novel therapeutic options are needed to help solve this problem. One such option is immunotherapy, which targets immune checkpoint molecules that inhibit cancer cells, decreasing immune system activation, for example, immunotherapies t...
Autores principales: | Suraya, Ratoe, Tachihara, Motoko, Nagano, Tatsuya, Nishimura, Yoshihiro, Kobayashi, Kazuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234310/ https://www.ncbi.nlm.nih.gov/pubmed/35769229 http://dx.doi.org/10.2147/CMAR.S366738 |
Ejemplares similares
-
Microbiome as a Target for Cancer Therapy
por: Suraya, Ratoe, et al.
Publicado: (2020) -
Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
por: Suraya, Ratoe, et al.
Publicado: (2022) -
Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Fukui, Takafumi, et al.
Publicado: (2022) -
Possible Biomarkers for Cancer Immunotherapy
por: Otoshi, Takehiro, et al.
Publicado: (2019) -
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)